Learn more about Peter Attia’s digital program
Silencing the alarm over a recent paper on dietary protein and atherosclerosis
A recent report that high protein intake contributes to atherosclerosis has limited relevance to anyone but transgenic mice
#276 ‒ Special episode: Peter answers questions on longevity, supplements, protein, fasting, apoB, statins, and more
“One of the most important things to understand when you are using some sort of intervention is, do you have a biomarker to know if you’re doing it correctly?” —Peter Attia
Could an antihypertensive drug have independent benefits for longevity?
A recent animal study indicates that the antihypertensive drug rilmenidine has impressive effects on lifespan, but without further evidence, this story seems like another “fountain of youth” myth.
#272 ‒ Rapamycin: potential longevity benefits, surge in popularity, unanswered questions, and more | David Sabatini, M.D., Ph.D. and Matt Kaeberlein, Ph.D.
“[Rapamycin] is the most robust and reproducible drug that we know about today for impacting not only longevity, but to the extent that we can measure various metrics of healthspan in complex animals, rapamycin also seems to positively impact pretty much every aspect of health span that we measure.” —Matt Kaeberlein
The cases for and against dietary protein for healthy aging
An endeavor to settle the debate of high- vs. low-protein diets for increasing lifespan and healthspan
#222 ‒ How nutrition impacts longevity | Matt Kaeberlein, Ph.D.
“It’s really important that we be willing to change our beliefs about nutrition and other aspects of health as more data comes in.” —Matt Kaeberlein
The challenges of defining aging with Matt Kaeberlein, Ph.D.
This video clip is from episode #175 – The biology of aging, rapamycin, and other interventions that target the aging…
#204 – Centenarians, metformin, and longevity | Nir Barzilai, M.D.
“If you prevent aging and age-related disease, you’re going to compress morbidity, too.” — Nir Barzilai
#175 – Matt Kaeberlein, Ph.D.: The biology of aging, rapamycin, and other interventions that target the aging process
“I don’t think I will ever understand aging fully. And I don’t think the field will. … But I also believe that we don’t have to understand it fully to be able to have an impact on the biology of aging through interventions.” —Matt Kaeberlein
Rapamycin risks?
The importance of good science and good interpretation